• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00
    Get the next $EBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 1,249 shares, decreasing direct ownership by 0.71% to 174,927 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:36 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Bioservices Hartzel William covered exercise/tax liability with 1,167 shares, decreasing direct ownership by 1% to 107,955 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:45 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Products Business Williams Paul Anthony covered exercise/tax liability with 464 shares, decreasing direct ownership by 0.54% to 85,871 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:27 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care